Evidence map›Paper›PMID 40761344›Full record

ArticleIJID regions2025

Prevalence and risk factors associated with infections linked to carbapenemase-producing

Cedric Fossi Tchinda, Karyom Djim-Adjim-Ngana, Therence Annie Mbogning, Brice Fredy Nemg Simo, Sosthene Boido Baira, Gaizirene Egoume Feudjieu, Sonia Gayap Matchuenkam, Gael Njini Nfor, Guy Roussel Nguemto Takuissu, Kikie Josiane Essola and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Cedric Fossi TchindaPharmacology and Drugs Discovery Laboratory, Centre for Research on Medicinal Plants and Traditional Medicine, Institute of Medical Research and Medicinal Plants Studies (IMPM), Yaoundé, Cameroon.
Karyom Djim-Adjim-NganaLaboratory of Microbiology, Infectious Diseases and Immunology, Centre for Research on Health and Priority Pathologies, Institute of Medical Research and Medicinal Plant Studies, Yaoundé, Cameroon.
Therence Annie MbogningDepartment of Clinical biology, Estuary Academic and Strategic Institute (IUEs/INSAM), University of Douala, Douala, Cameroon.
Brice Fredy Nemg SimoCentre for Research in Infectious Disease, Yaoundé, Cameroon.
Sosthene Boido BairaKaele District Hospital, Ministry of Public Health, Kaele, Cameroon.
Gaizirene Egoume FeudjieuPharmacology and Drugs Discovery Laboratory, Centre for Research on Medicinal Plants and Traditional Medicine, Institute of Medical Research and Medicinal Plants Studies (IMPM), Yaoundé, Cameroon.
Sonia Gayap MatchuenkamPharmacology and Drugs Discovery Laboratory, Centre for Research on Medicinal Plants and Traditional Medicine, Institute of Medical Research and Medicinal Plants Studies (IMPM), Yaoundé, Cameroon.
Gael Njini NforPharmacology and Drugs Discovery Laboratory, Centre for Research on Medicinal Plants and Traditional Medicine, Institute of Medical Research and Medicinal Plants Studies (IMPM), Yaoundé, Cameroon.
Guy Roussel Nguemto TakuissuCentre for Food, Food Security and Nutrition Research, Institute of Medical Research and Medicinal Plants Studies (IMPM), Yaoundé, Cameroon.
Kikie Josiane EssolaFaculty of Medicine and Pharmaceutical Sciences of the University of Douala, Douala, Cameroon.
Connie Constance Georgina WalyaroInternational Society for Infectious Diseases (ISID), European and Developing Countries Clinical Trials Partnership (EDCTP), Talk AB[M]R, Nairobi, Kenya.
Armelle Deutou TchamgouePharmacology and Drugs Discovery Laboratory, Centre for Research on Medicinal Plants and Traditional Medicine, Institute of Medical Research and Medicinal Plants Studies (IMPM), Yaoundé, Cameroon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Carbapenems are critical antibiotics used against multidrug-resistant infections, yet resistance is increasing, especially among Gram-negative bacteria like Methods: A 6-month prospective cross-sectional study (April-September 2024) was conducted using 531 clinical samples from four health facilities. Strains were identified via morphologic, biochemical, and API 20 NE® tests. Antibiotic susceptibility was assessed using disc diffusion, and carbapenemases were characterized phenotypically. Results: Of the samples, 4.9% yielded Conclusions: These findings highlight an urgent need for better surveillance, stricter antibiotic stewardship, and enhanced infection control strategies to limit the spread of resistant

Indexed as

AcinetobacterCarbapenemaseHealth facilitiesPrevalenceRisk factorsYaoundé

Identifiers

PMID40761344
PMCPMC12319547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.